Oxford Nanopore Technologies has partnered with US-based company Fabric Genomics to develop a software solution that can analyse and report on genomic data from neonatal and paediatric patients in intensive care units.
According to the companies, the goal is to provide genetic insights that can help clinicians diagnose rare genetic disorders in children.
The partnership aims to streamline the analysis process, connecting UK-based Oxford Nanopore’s EPI2ME sequencing technology with Fabric Genomics AI-driven whole genome sequence solution.
The software will initially focus on the highest complexity testing for paediatrics in the NICU, but the companies said they expect to launch additional push-button solutions for late-onset genetic conditions, including cancer and cardiovascular disease.
The new platform is currently available on a limited basis but will be rolled out widely available from Q1 2024.
Earlier this month, French diagnostics company bioMérieux invested £70m ($85m) into Oxford Nanopore Technologies as part of an investment to advance Oxford Nanopore’s in-vitro diagnostic (IVD) solution.
In June 2023, Oxford Nanopore partnered with Genetex for the development of a software solution for end-to-end analysis and clinical reporting of nanopore sequencing data. This platform is also integrated with Oxford Nanopore’s EPI2ME, to conduct the secondary sequence analysis.
Oxford Nanopore reported revenues of £198.6m ($242.1m) for the fiscal year ended December 2022 (FY2022), an increase of 48.6% over FY2021.
Fabric Genomics CEO and co-founder Martin Reese said: “Oxford Nanopore’s real-time genomic reading technology represents an important opportunity to speed the critical analysis of children’s genomes in NICU settings and for all genomic medicine patients.”
